Anti-Human HIF1A Polyclonal Antibody (HS858014)

데이터시트 제품 공유 정보 복사

가격(USD): $

사양:

50ug
100ug

수량:

문의하기

개요
이미지
참고 문헌
데이터시트

개요

카탈로그 번호

HS858014

설명

Anti-Human HIF1A Polyclonal Antibody (HS858014) is a rabbit polyclonal antibody detecting HIF1A in ELISA, IHC, WB. Suitable for Human.

Highlights

●Affinity Purified — Minimal background and high purity for reliable results.
●Multi-Application — Validated across multiple applications.

종 반응성

Human

응용 분야

ELISA, IHC, WB

숙주 종

Rabbit

이소타입

IgG

클론성

Polyclonal

면역원

E. coli - derived recombinant Human HIF1A (Asp55-Val342).

타겟

Hypoxia-inducible factor 1-alpha, HIF-1-alpha, HIF1-alpha, ARNT-interacting protein, Basic-helix-loop-helix-PAS protein MOP1, Class E basic helix-loop-helix protein 78, bHLHe78, Member of PAS protein 1, PAS domain-containing protein 8, HIF1A, BHLHE78, MOP1, PASD8

정제

Purified by antigen affinity column.

등록번호

Q16665

RRID

Anti-Human HIF1A Polyclonal Antibody (abinScience Cat# HS858014, RRID:AB_3724606)

형태

Liquid

저장 완충액

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요.

제품 사용 정보

응용 분야	희석
ELISA	1:5000-1:20000
IHC	1:50-1:500
WB	1:500-1:2000

안정성 및 저장

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

배경

Hypoxia-inducible factor 1-alpha (HIF1A) is a ~92 kDa protein. Functions as a master transcriptional regulator of the adaptive response to hypoxia. Under hypoxic conditions, activates the transcription of over 40 genes, including erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor, HILPDA, and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia. Plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease. Heterodimerizes with ARNT; heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters. Activation requires recruitment of transcriptional coactivators such as CREBBP and EP300.

1. Jaakkola, P. et al. (2001) Science (New York, N.Y.) 292, 468-72. PMID: 11292861

2. Masson, N. et al. (2001) The EMBO journal 20, 5197-206. PMID: 11566883

3. Bae, SH. et al. (2004) Biochemical and biophysical research communications 324, 394-400. PMID: 15465032

4. Choi, SM. et al. (2006) The Journal of biological chemistry 281, 34056-63. PMID: 16973622

5. Berta, MA. et al. (2007) Biochemical and biophysical research communications 360, 646-52. PMID: 17610843

6. Kim, EJ. et al. (2008) Arteriosclerosis, thrombosis, and vascular biology 28, 1796-802. PMID: 18658046

7. Gimm, T. et al. (2010) FASEB journal : official publication of the Federation of American Societies for Experimental Biology 24, 4443-58. PMID: 20624928

8. Shan, B. et al. (2012) Endocrine-related cancer 19, 13-27. PMID: 22009797

9. Xu, C. et al. (2018) PLoS pathogens 14, e1007259. PMID: 30125331

10. Bhattacharya, S. et al. (1999) Genes & development 13, 64-75. PMID: 9887100

참고사항

For research use only.

이미지

참고 문헌

데이터시트